Acetamide,2-amino-N-[2-(dimethylamino)ethyl]-

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Acetamide,2-amino-N-[2-(dimethylamino)ethyl]-
• 英文别名: 2-amino-N-[2-(dimethylamino)ethyl]acetamide
• 化学式: C₆H₁₅N₃O
• 分子量: 145.2
• InChiKey: RAPLOFPMGSYVQW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  58.4
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF<br/>[FR] DÉRIVÉ DE GLUCOPYRANOSYLE ET UTILISATION ASSOCIÉE
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2019144864A1

  公开（公告）日：2019-08-01

  Provided are a glucopyranosyl derivative as a sodium-dependent glucose transporters inhibitor, especially as a SGLT1 inhibitor, a pharmaceutically acceptable salt or a stereoisomer thereof, a pharmaceutical composition thereof, and the uses of the compound and pharmaceutical composition thereof in the preparation of drugs for the treatment of diabetes and diabetes-related diseases.

  提供一种葡萄糖吡喃基衍生物作为一种钠依赖性葡萄糖转运蛋白抑制剂，特别是作为SGLT1抑制剂，其药用可接受盐或其立体异构体，以及其药物组合物，以及该化合物和药物组合物在制备用于治疗糖尿病和糖尿病相关疾病的药物中的用途。
• Glucopyranosyl derivative and use thereof
  申请人：SUNSHINE LAKE PHARMA CO., LTD.

  公开号：US11084842B2

  公开（公告）日：2021-08-10

  A glucopyranosyl derivative as a sodium-dependent glucose transporters inhibitor, especially as a SGLT1 inhibitor, a pharmaceutically acceptable salt or a stereoisomer thereof, a pharmaceutical composition thereof, and the uses of the compound and pharmaceutical composition thereof in the preparation of drugs for the treatment of diabetes and diabetes-related diseases.

  一种作为钠依赖性葡萄糖转运体抑制剂，特别是作为 SGLT1 抑制剂的葡萄糖吡喃糖基衍生物、其药学上可接受的盐或立体异构体、其药物组合物，以及该化合物及其药物组合物在制备治疗糖尿病和糖尿病相关疾病的药物中的用途。
• GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES
  申请人：AstraZeneca AB

  公开号：EP1296973A1

  公开（公告）日：2003-04-02
• GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF
  申请人：SUNSHINE LAKE PHARMA CO., LTD.

  公开号：US20210061839A1

  公开（公告）日：2021-03-04

  A glucopyranosyl derivative as a sodium-dependent glucose transporters inhibitor, especially as a SGLT1 inhibitor, a pharmaceutically acceptable salt or a stereoisomer thereof, a pharmaceutical composition thereof, and the uses of the compound and pharmaceutical composition thereof in the preparation of drugs for the treatment of diabetes and diabetes-related diseases.
• US7001904B1
  申请人：——

  公开号：US7001904B1

  公开（公告）日：2006-02-21